Delving into the Latest Updates on Shenzhen Hemu Gene Biotechnology Co. Ltd. with Synapse

Overview

Tags

Hemic and Lymphatic Diseases

Other Diseases

Congenital Disorders

CRISPR/Cas9

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Hemic and Lymphatic Diseases	3
Immune System Diseases	2
Nervous System Diseases	1
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

CRISPR/Cas9	5

Top 5 Target	Count

β-globin(Hemoglobin beta chain)	1
ASA(Cerebroside-sulfatase)	1
IL-2Rγ(Interleukin-2 receptor subunit gamma)	1
Hemoglobin HbA	1

This is a single-arm, open label, multi-center, single-dose Phase 1 clinical trial in subjects with transfusion dependent β-thalassaemia. The study aims to evaluate the safety and efficacy of autologous lentiviral-transduced CD34+ human hematopoietic stem cells (hHSCs) using the gene therapy product HGI-001.

Start Date12 Jun 2024

Sponsor / Collaborator

Shenzhen Hemu Gene Biotechnology Co. Ltd.

NCT05851105

/ RecruitingEarly Phase 1

the Safety and Efficacy Evaluation of HGI-002 Injection in Patients With Transfusion-Dependent α-Thalassemia

This is an open label study to evaluate the safety and efficacy of α-globin Restored Autologous Hematopoietic Stem Cells in α-Thalassemia Major Patients

Start Date08 Oct 2022

Sponsor / Collaborator

Shenzhen Hemu Gene Biotechnology Co. Ltd.

NCT05864170

/ RecruitingEarly Phase 1

the Safety and Efficacy Evaluation of HGI-001 Injection in Patients With Transfusion-Dependent β-Thalassemia(Child)

This is an open label study to evaluate the safety and efficacy of β-globin Restored Autologous Hematopoietic Stem Cells in ß-Thalassemia Major Patients

Start Date27 May 2022

Sponsor / Collaborator

Shenzhen Hemu Gene Biotechnology Co. Ltd.

100 Clinical Results associated with Shenzhen Hemu Gene Biotechnology Co. Ltd.

Login to view more data

0 Patents (Medical) associated with Shenzhen Hemu Gene Biotechnology Co. Ltd.

Login to view more data

100 Deals associated with Shenzhen Hemu Gene Biotechnology Co. Ltd.

Login to view more data

100 Translational Medicine associated with Shenzhen Hemu Gene Biotechnology Co. Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 16 Aug 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

3

1

Early Phase 1

Phase 2

1

6

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

β-globin restored autologous hematopoietic stem cells (Hemogen Gene) ( β-globin )	Transfusion-dependent Beta Thalassemia More	Phase 1/2
α-globin restored autologous hematopoietic stem cells(Shenzhen Hemogen) ( Hemoglobin HbA )	Alpha-Thalassemia More	Early Phase 1
HGI-003 ( IL-2Rγ )	X-Linked Combined Immunodeficiency Diseases More	Preclinical
HGI-005 ( ASA )	Neurodegenerative Diseases More	Preclinical
HGI-004	Wiskott-Aldrich Syndrome More	Preclinical